<DOC>
	<DOCNO>NCT00979706</DOCNO>
	<brief_summary>Pilot study treatment primary HIV infection objective induce strong specific HIV immune response able control viral replication without HAART .</brief_summary>
	<brief_title>Immune-based Therapy Pilot Study Treatment Primary HIV Infection ( PHI-IMD ) .</brief_title>
	<detailed_description>Pilot open RCT 20 patient primary HIV-1 infection randomize one two arm : 1 ) Control arm ( A ) , Tenofovir +Lamivudine + Lopinavir-ritonavir ( Kaletra ) standard dose 44 week ( W44 ) ; short treatment interruption ( TI ) perform W36 , HAART restart 8 week plasma HIV-1 RNA viral load ( pVL ) rebound &gt; 200 copies/mL . At W44 HAART stop patient follow 48 additional week ( W92 ) . 2 ) Immune-based arm ( B ) , HAART schedule plus oral cyclosporine A ( CsA ) ( serum level 250-350 mcg/L ) first 8 week HAART . During TI , patient receive sc GM-CSF ( 250 mcg TIW ) plus weekly sc pegylated-interferon a2b ( Peg-INF ) ( 1.5 mcg/kg/week ) . During last 8 week HAART ( W44 ) , patient receive daily sc low-dose interleukin-2 ( IL-2 ) ( 0.75 MU/kg QD ) . The primary endpoint pVL &lt; 1000copies/mL ( &lt; 3.0 log10/mL ) 12 ( W56 ) 48 ( W92 ) week stop HAART . Sample size calculate order detect pVL difference 1.5log10 copies/mL 12 ( W56 ) week stop HAART control immune-based arm power 80 % level significance of0.05 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . HIVinfected patient ( age 18 year ) primary HIV infection &lt; 90 day . 2 . Giving write informed consent participate study . 1 . Patients accept start HAART . Patients wish start HAART treatment nevirapine efavirenz . 2 . Pregnant woman plan pregnancy . 3 . Intravenous drug user alcohol abuse . 4 . Previous treatment cyclosporin A , GMCSF , pegylatedinterferonalpha interleukine2 . 5 . Renal liver failure . 6 . Any formal contraindication treatment study drug . 7 . Patients history psychiatric disorder , thyroid illness , dislipidemia require treatment , cardiovascular disease , arterial hypertension , diabetes mellitus . 8 . In treatment drug interact study drug . 9 . Acute infection HTLVI EBV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>